Harmony Net Income From Continuing Ops from 2010 to 2025
| HRMY Stock | USD 35.28 0.38 1.09% |
Net Income From Continuing Ops | First Reported 2019-06-30 | Previous Quarter 46.1 M | Current Value 49.5 M | Quarterly Volatility 30.8 M |
Check Harmony Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Harmony Biosciences' main balance sheet or income statement drivers, such as Tax Provision of 48.6 M, Net Interest Income of 1.1 M or Depreciation And Amortization of 16.4 M, as well as many indicators such as Price To Sales Ratio of 2.6, Dividend Yield of 0.0 or PTB Ratio of 3.12. Harmony financial statements analysis is a perfect complement when working with Harmony Biosciences Valuation or Volatility modules.
Harmony | Net Income From Continuing Ops |
Latest Harmony Biosciences' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Harmony Biosciences Holdings over the last few years. It is Harmony Biosciences' Net Income From Continuing Ops historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Harmony Biosciences' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Harmony Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | 7,317,353 | |
| Coefficient Of Variation | 1,317 | |
| Mean Deviation | 78,561,736 | |
| Median | (39,898,000) | |
| Standard Deviation | 96,364,810 | |
| Sample Variance | 9286.2T | |
| Range | 333.4M | |
| R-Value | 0.70 | |
| Mean Square Error | 5119.7T | |
| R-Squared | 0.49 | |
| Significance | 0 | |
| Slope | 14,102,269 | |
| Total Sum of Squares | 139292.6T |
Harmony Net Income From Continuing Ops History
About Harmony Biosciences Financial Statements
Harmony Biosciences investors use historical fundamental indicators, such as Harmony Biosciences' Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Harmony Biosciences. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Income From Continuing Ops | 145.5 M | 152.8 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Harmony Stock Analysis
When running Harmony Biosciences' price analysis, check to measure Harmony Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Harmony Biosciences is operating at the current time. Most of Harmony Biosciences' value examination focuses on studying past and present price action to predict the probability of Harmony Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Harmony Biosciences' price. Additionally, you may evaluate how the addition of Harmony Biosciences to your portfolios can decrease your overall portfolio volatility.